Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.

ABSTRACT:

Objectives

Pharmacologic evidence suggests adequate antiplatelet activity in diabetic patients requires >100 mg aspirin daily, yet recent trials have used ≤100 mg daily. This meta-analysis explored the relationship between aspirin dose and prevention of cardiovascular events.

Data sources

Six electronic databases were searched using database-appropriate terms for aspirin, diabetes, and comparative study from inception until February 2010.

Review methods

Randomized controlled trials and cohort studies comparing aspirin to no antiplatelet therapy were included if they reported cardiovascular events as pre-specified outcomes, aspirin dose, and number of diabetic patients. Studies were stratified by daily aspirin dose (≤100 mg; 101-325 mg; >325 mg) and pooled risk ratios

SUBMITTER: Simpson SH 

PROVIDER: S-EPMC3208465 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature